As a practicing physician, it's amazing that the "negative outlook" posters on this stock would actually mention the product not being good or useful. I can see bashing it as overvalued, mismanaged as a company, too early to see what true valuation is, etc. But mentioning skin area, usefulness in burns vs skin lesions, etc. It is WAAAYYY better from any physicians perspective that anything available. AND it's approved. When I say WAAAYY better, that means cost effectiveness, decreased scarring, decreased donor site morbidity,it will prove less infection rate as well. What more could it be better at clinically? Focus your attacks on management and the company not following the best path. It severely discredits your arguments when usefulness/non-novelty is mentioned.
- Forums
- ASX - By Stock
- AVH
- Ann: Pivotal Soft Tissue Trial Receives US FDA IDE Approval
Ann: Pivotal Soft Tissue Trial Receives US FDA IDE Approval, page-35
-
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AVH (ASX) to my watchlist
(20min delay)
|
|||||
Last
$2.53 |
Change
-0.200(7.33%) |
Mkt cap ! $172.2M |
Open | High | Low | Value | Volume |
$2.59 | $2.61 | $2.53 | $1.062M | 413.3K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
5 | 15328 | $2.53 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$2.54 | 812 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
5 | 15328 | 2.530 |
4 | 29926 | 2.520 |
2 | 5085 | 2.510 |
14 | 30180 | 2.500 |
1 | 10000 | 2.490 |
Price($) | Vol. | No. |
---|---|---|
2.540 | 812 | 1 |
2.560 | 31376 | 3 |
2.600 | 11000 | 2 |
2.610 | 3000 | 2 |
2.620 | 7200 | 2 |
Last trade - 16.10pm 05/08/2024 (20 minute delay) ? |
Featured News
AVH (ASX) Chart |